Comparative Pharmacology
Head-to-head clinical analysis: IMPLANON versus NIKITA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPLANON versus NIKITA.
IMPLANON vs NIKITA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etonogestrel, a progestin, binds to progesterone and androgen receptors, suppressing gonadotropin release (FSH, LH) and preventing ovulation. It also increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial morphology.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the serotonin transporter (SERT).
Insert 1 rod (68 mg etonogestrel) subdermally in the inner upper arm; replacement every 3 years.
NIKITA is not a recognized pharmaceutical agent; no standard dosing information is available.
None Documented
None Documented
Terminal elimination half-life is approximately 25-30 hours; significant interindividual variability
Terminal elimination half-life is 12 hours (range 10-14 hours); permits twice-daily dosing in most patients with normal renal function.
Metabolites primarily excreted in urine (approximately 50%) and feces (30-35%)
Primarily renal (approx. 60% unchanged), with biliary/fecal excretion accounting for 30% and minor metabolic clearance.
Category C
Category C
Contraceptive
Contraceptive